Medtronic announced on February 3, 2026, its intent to exercise its option to acquire CathWorks, an Israeli medical device company specializing in AI-driven coronary artery disease diagnostics, in a deal valued at up to $585 million plus potential undisclosed earn-out payments. The acquisition, pending U.S. Federal Trade Commission clearance, is expected to close by the end of Medtronic’s fiscal year 2026.
The move marks an expansion of Medtronic’s interventional cardiology portfolio, bringing in-house CathWorks’ FFRangio® System — a technology that allows access to coronary artery blockages without invasive pressure wires. The system transforms standard coronary angiograms (X-rays) into comprehensive physiological assessments of the entire coronary tree, providing fractional flow reserve (FFR) measurements that help physicians determine which patients need coronary intervention.
“Through our co-promotion agreement, we’ve seen how CathWorks can disrupt the traditional wire-based FFR segment and leverage the power of data and AI to deliver innovative solutions,” said Jason Weidman, senior vice president and president of Medtronic’s Coronary & Renal Denervation business. “This acquisition allows Medtronic to transform the cath lab with technology that provides real-time data, informs individualized treatment approaches, and drives new standards of care.”
The acquisition follows a 2022 partnership under which Medtronic co-promoted the FFRangio System in the U.S., Europe, and Japan. According to CathWorks CEO Ramin Mousavi, this three-year collaboration unlocked significant market opportunities through expanded utilization of the technology.
FFR is a diagnostic tool that helps cardiologists identify which arterial blockages actually cause ischemia, enabling appropriate treatment for patients who need it while avoiding unnecessary procedures for those who don’t.
Traditional wire-based FFR remains underutilized mainly due to its invasive nature, and measurements are limited to single locations within vessels.
CathWorks’ AI-driven approach helps to overcome these limitations by delivering FFR values along the entire coronary tree directly from routine angiograms, with clinical studies demonstrating excellent diagnostic accuracy compared to wire-based methods. The system also provides intraprocedural optimization tools, including assessment of physiological impact after lesion treatment and interactive sizing capabilities.
The acquisition is expected to have an immaterial impact on Medtronic’s fiscal 2027 GAAP and adjusted earnings per share, with neutral to accretive effects thereafter. Until deal closure, both companies will continue operating independently.
CathWorks, based in Kfar Saba, Israel, will become part of Medtronic’s Cardiovascular Portfolio upon completion of the transaction.